Buy Braftovi in India — Price & Availability

Braftovi (encorafenib) is an oral kinase inhibitor that blocks the activity of the mutated BRAF protein. In cancers with a BRAF V600 mutation, this protein drives uncontrolled cell growth; encorafenib is given together with other targeted medicines to block this signalling more completely.

It is approved for:

• Melanoma — in combination with binimetinib (Mektovi), for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
• Metastatic colorectal cancer (mCRC) — in combination with cetuximab and fluorouracil-based chemotherapy for BRAF V600E-mutated mCRC, and in combination with cetuximab for BRAF V600E-mutated mCRC after prior therapy.
• Metastatic non-small cell lung cancer (NSCLC) — in combination with binimetinib, for BRAF V600E-mutated metastatic NSCLC.

The BRAF mutation must be confirmed by an approved test before treatment. Braftovi is not for patients with wild-type BRAF tumours. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:
The recommended dose of Braftovi depends on the cancer being treated and the medicines it is combined with:

• Melanoma: 450 mg (six 75 mg capsules) orally once daily, with binimetinib.
• Metastatic NSCLC: 450 mg once daily, with binimetinib.
• Metastatic colorectal cancer: 300 mg (four 75 mg capsules) orally once daily, with cetuximab (with or without fluorouracil-based chemotherapy).

Braftovi is taken with or without food, at about the same time each day, until disease progression or unacceptable toxicity. Grapefruit and grapefruit juice should be avoided, and strong or moderate CYP3A inhibitors/inducers may require dose adjustment. The treating oncologist always determines the exact dose and any modifications.

Braftovi’s prescribing information includes the following key warnings and precautions:

• New primary malignancies: new skin cancers (cutaneous) and non-cutaneous cancers can occur; report any new or changing skin lesions promptly.
• Tumour promotion in BRAF wild-type tumours: Braftovi is not used in wild-type BRAF cancers, as it may promote their growth.
• Cardiomyopathy: heart function (ejection fraction) is monitored.
• Hepatotoxicity: liver enzymes are monitored during treatment.
• Hemorrhage, uveitis (eye inflammation), and QT prolongation: monitored and managed as needed.
• Embryo-fetal toxicity: Braftovi can harm an unborn baby; effective contraception is advised, and non-hormonal methods may be recommended since encorafenib can reduce the effectiveness of hormonal contraceptives.

Common side effects: Common side effects vary by regimen and may include fatigue, nausea, vomiting, diarrhoea, abdominal pain, joint and muscle pain, headache, rash and other skin changes, and altered blood tests. This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Braftovi through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Import & delivery — Braftovi is sourced and shipped under validated, temperature-controlled conditions to the patient or treating hospital.

Documents required to import Braftovi:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including BRAF V600E/V600K mutation test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Braftovi is not sold on the open market in India, there is no fixed MRP. The Braftovi cost in India depends on a few factors at the time of import:

• The number of 75 mg capsules and the pack size required per cycle, which is based on the prescribed daily dose (this varies by indication — for example, 450 mg once daily in melanoma and 300 mg once daily in colorectal cancer).
  The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Braftovi cost, logistics, and delivery timeline once a valid prescription is shared. Request your Braftovi quote →

Braftovi is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Braftovi from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. Braftovi capsules are stored at room temperature, 20 °C to 25 °C (68 °F to 77 °F), with excursions permitted between 15 °C and 30 °C, in the original bottle. Braftovi is moisture-sensitive: keep the container tightly closed, do not remove the desiccant, and protect from moisture. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Braftovi available in India?

Braftovi (encorafenib capsules) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Braftovi is not commercially marketed in India.

However, patients in India can legally access Braftovi through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Braftovi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Braftovi price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada,
• Europe, and Australia
  Ensuring full transparency throughout the process

Braftovi can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Braftovi first received US FDA approval on 27 June 2018, in combination with binimetinib, for BRAF V600E/V600K-mutated unresectable or metastatic melanoma. The FDA later approved it for BRAF V600E-mutated metastatic colorectal cancer (2020, with cetuximab; with a 2024 accelerated approval and subsequent traditional approval for the cetuximab plus chemotherapy regimen) and for BRAF V600E-mutated metastatic NSCLC (October 2023, with binimetinib). It is also approved in the European Union and other markets. As of the current publicly available information, Braftovi is not commercially marketed in India, which is why the Named Patient route is used.